Literature DB >> 7695277

In vitro and ex vivo effects of cyclosporin A on phagocytic host defenses against Aspergillus fumigatus.

E Roilides1, T Robinson, T Sein, P A Pizzo, T J Walsh.   

Abstract

Because cyclosporin A (CsA) is extensively used as an immunosuppressive agent, its effects on phagocytic defenses against Aspergillus fumigatus were studied in vitro and ex vivo. After incubation with 10 to 250 ng of CsA per ml at 37 degrees C for 60 min, polymorphonuclear leukocytes (PMNs) exhibited unaltered superoxide anion (O2-) production in response to phorbol myristate acetate and N-formylmethionyl leucyl phenylalanine, whereas > or = 500 ng/ml significantly suppressed it (P < 0.01). Moreover, at < 250 ng of CsA per ml, PMNs exhibited no change in their capacity to damage unopsonized hyphae of A. fumigatus compared with controls, whereas at > or = 250 ng/ml, CsA suppressed the function (P < 0.01). Although neither CsA (250 ng/ml) nor hydrocortisone (10 micrograms/ml) suppressed PMN O2- production in response to phorbol myristate acetate and N-formylmethionyl leucyl phenylalanine, combination of the two agents reduced the function compared with that at the baseline (P < 0.05). Incubation of monocytes with 100 ng of CsA per ml for 1 or 2 days suppressed their antihyphal activity. No essential change in phagocytic activity of monocyte-derived macrophages (MDMs) against A. fumigatus conidia, tested as the percentage of phagocytosing MDMs and average number of MDM-associated conidia, was detected after 2 or 4 days of incubation with 10 to 1,000 ng of CsA per ml. Furthermore, in rabbits treated with CsA (up to 20 mg/kg of body weight per day intravenously for 7 days), neither O2- production and hyphal damage caused by PMNs or monocytes against hyphae nor phagocytosis of conidia by pulmonary alveolar macrophages was significantly suppressed. Thus, these results demonstrated that CsA within therapeutically relevant concentrations does not suppress antifungal activity of phagocytes except that of circulating monocytes. However, it may induce significant immunosuppression of phagocytes' antifungal function at relatively high concentrations in vitro, especially when combined with corticosteroids.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7695277      PMCID: PMC188301          DOI: 10.1128/AAC.38.12.2883

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  Stimulatory effect of counterflow centrifugal elutriation in large-scale separation of peripheral blood monocytes can be reversed by storing the cells at 37 degrees C.

Authors:  T G Abrahamsen; C S Carter; E J Read; M Rubin; H G Goetzman; E F Lizzio; Y L Lee; M Hanson; P A Pizzo; T Hoffman
Journal:  J Clin Apher       Date:  1991       Impact factor: 2.821

2.  Unopsonized Candida albicans hyphae stimulate a neutrophil respiratory burst and a cytosolic calcium flux without membrane depolarization.

Authors:  C A Lyman; E R Simons; D A Melnick; R D Diamond
Journal:  J Infect Dis       Date:  1987-11       Impact factor: 5.226

3.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

4.  In vitro killing of spores and hyphae of Aspergillus fumigatus and Rhizopus oryzae by rabbit neutrophil cationic peptides and bronchoalveolar macrophages.

Authors:  S M Levitz; M E Selsted; T Ganz; R I Lehrer; R D Diamond
Journal:  J Infect Dis       Date:  1986-09       Impact factor: 5.226

5.  Impairment of neutrophil chemotactic and bactericidal function in children infected with human immunodeficiency virus type 1 and partial reversal after in vitro exposure to granulocyte-macrophage colony-stimulating factor.

Authors:  E Roilides; S Mertins; J Eddy; T J Walsh; P A Pizzo; M Rubin
Journal:  J Pediatr       Date:  1990-10       Impact factor: 4.406

6.  In vivo bronchoalveolar macrophage defense against Rhizopus oryzae and Aspergillus fumigatus.

Authors:  A R Waldorf; S M Levitz; R D Diamond
Journal:  J Infect Dis       Date:  1984-11       Impact factor: 5.226

7.  Immunosuppressive effect of cyclosporin A on resistance to systemic infection with Candida albicans.

Authors:  A Vecchiarelli; E Cenci; P Marconi; R Rossi; C Riccardi; F Bistoni
Journal:  J Med Microbiol       Date:  1989-11       Impact factor: 2.472

8.  Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon.

Authors:  E Roilides; K Uhlig; D Venzon; P A Pizzo; T J Walsh
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

9.  Effect of cyclosporin A on human neutrophil and monocyte function.

Authors:  A Kharazmi; M Svenson; H Nielsen; H S Birgens
Journal:  Scand J Immunol       Date:  1985-06       Impact factor: 3.487

10.  Early infections in kidney, heart, and liver transplant recipients on cyclosporine.

Authors:  J S Dummer; A Hardy; A Poorsattar; M Ho
Journal:  Transplantation       Date:  1983-09       Impact factor: 4.939

View more
  5 in total

1.  In vitro effect of cefodizime, imipenem/cilastatin and co-trimoxazole on dexamethasone and cyclosporin A depressed phagocytosis.

Authors:  A Dhondt; R Vanholder; M A Waterloos; G Glorieux; R De Smet; S Ringoir
Journal:  Infection       Date:  1998 Mar-Apr       Impact factor: 3.553

2.  Treatment of Cyclosporin A retains host defense against invasive pulmonary aspergillosis in a non-immunosuppressive murine model by preserving the myeloid cell population.

Authors:  Sarah Sze Wah Wong; Orhan Rasid; Paris Laskaris; Arnaud Fekkar; Jean-Marc Cavaillon; William J Steinbach; Oumaima Ibrahim-Granet
Journal:  Virulence       Date:  2017-07-06       Impact factor: 5.882

Review 3.  Aspergillus fumigatus and aspergillosis.

Authors:  J P Latgé
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

4.  Cyclosporine A impairs nucleotide binding oligomerization domain (Nod1)-mediated innate antibacterial renal defenses in mice and human transplant recipients.

Authors:  Emilie Tourneur; Sanae Ben Mkaddem; Cécilia Chassin; Marcelle Bens; Jean-Michel Goujon; Nicolas Charles; Christophe Pellefigues; Meryem Aloulou; Alexandre Hertig; Renato C Monteiro; Stephen E Girardin; Dana J Philpott; Eric Rondeau; Carole Elbim; Catherine Werts; Alain Vandewalle
Journal:  PLoS Pathog       Date:  2013-01-31       Impact factor: 6.823

5.  Cyclosporine A plus low-dose steroid treatment in COVID-19 improves clinical outcomes in patients with moderate to severe disease: A pilot study.

Authors:  J L Gálvez-Romero; O Palmeros-Rojas; F A Real-Ramírez; S Sánchez-Romero; R Tome-Maxil; M P Ramírez-Sandoval; R Olivos-Rodríguez; S E Flores-Encarnación; A A Cabrera-Estrada; J Ávila-Morales; V Cortés-Sánchez; G Sarmiento-Padilla; S E Tezmol-Ramírez; D Aparicio-Hernández; M I Urbina-Sánchez; M Á Gómez-Pluma; S Cisneros-Méndez; D I Rodríguez-Rivas; S Reyes-Inurrigarro; G Cortés-Díaz; C Cruz-Delgado; J Navarro-González; J Deveaux-Homs; S Pedraza-Sánchez
Journal:  J Intern Med       Date:  2021-02-02       Impact factor: 13.068

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.